Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
